TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15521216
Drug: Ozonated autohemotherapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozonated autohemotherapy (O3‐AHT) with ozone concentration of 50 microg/ml
Study: 9726386
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg lansoprazole/day
Study: 9726386
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ranitidine/day
Study: 9726386
Drug: Termination of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Termination of therapy
Study: 8027291
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml insemination
Study: 8027291
Drug: 0.25 ml
Normalized name: mineral oil 0.25 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 ml insemination
Study: 2572101
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with MC 903 (new synthetic vitamin D3 analogue)
Study: 28522917
Drug: Xiangbin prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiangbin prescription (XBP)
Study: 23893178
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (partial substitution)
Study: 9183321
Drug: Wheat starch-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat starch-containing product (4 to 6 portions daily for up to 1 year)
Study: 31130959
Drug: Glucocorticosteroids and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticosteroids and/or adjuvant immunosuppressive drugs
Study: 31130959
Drug: Novel treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel treatment targets
Study: 23867622
Drug: Daily 2-hour
Normalized name: Deponit 0.2 MG/HR Daily Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 2-hour cold exposure at 17°C for 6 weeks
Study: 23867622
Drug: Daily ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily ingestion of capsinoids for 6 weeks
Study: 16361874
Drug: Brief Strategic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Strategic Family Therapy (BSFT) for 3 months
Study: 8968170
Drug: Diltiazem (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (60 mg orally 2 h before induction and an infusion of 0.1 mg.kg‐1.h‐1 for 23 h)
Study: 1477874
Drug: artemether (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: artemether (n = 24), 9.6 mg/kg body weight intramuscularly over five days
Study: 1477874
Drug: chloroquine (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: chloroquine (n = 23), 25 mg/kg body weight orally
Study: 3511402
Drug: Progabide (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progabide (32 mg/kg mean daily dose, range 16 to 63)
Study: 22082089
Drug: PROMETA Protocol
Normalized name: Promacta
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PROMETA Protocol (flumazenil 2 mg infusions on days 1, 2, 3, 22, 23; gabapentin 1200 mg to day 40; hydroxazine 50 mg to day 10)
Study: 22082089
Drug: Placebo medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medication (with active hydroxazine only)
Study: 12664022
Drug: Mizolastine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine (10 mg, once daily)
Study: 10630824
Drug: Cefepime administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime administered as an intravenous bolus or as a rapid infusion
Study: 2355106
Drug: HP 029
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP 029 at 450 mg/day (150 mg three times a day)
Study: 2355106
Drug: HP 029
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP 029 at 300 mg/day (100 mg three times a day)
Study: 2355106
Drug: HP 029
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP 029 at 225 mg/day (75 mg three times a day)
Study: 322539
Drug: Pethidine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine at two dose levels
Study: 23764202
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist withdrawal
Study: 23764202
Drug: Control (non-withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (non-withdrawal of GnRH agonist)
Study: 17146416
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER 75-300 mg/day
Study: 14633326
Drug: Trastuzumab added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab added to standard chemotherapy in HER2 positive metastatic breast cancer
Study: 11052243
Drug: Intravenous thiopental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thiopental followed by mask inhalation with 100% O2 and 1.13% halothane
Study: 11052243
Drug: Intravenous thiopental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thiopental followed by mask inhalation with 2.52% enflurane
Study: 11052243
Drug: Intravenous thiopental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thiopental followed by mask inhalation with 1.73% isoflurane
Study: 11052243
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam and ketamine
Study: 11052243
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam and alfentanil
Study: 3769402
Drug: Capsaicin injection
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin injection (0.5 micrograms/kg and 4 micrograms/kg)
Study: 3769402
Drug: Capsaicin injection
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin injection after inhalation of 5% bupivacaine aerosol
Study: 3769402
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution (not specified)
Study: 21036883
Drug: TPF induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF induction chemotherapy plus chemoradiotherapy
Study: 18416793
Drug: Acupressure and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure and meridian massage (15 minutes per session, 3 times daily for 10 days)
Study: 6452793
Drug: Zimelidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine (100 mg b.i.d.)
Study: 2939691
Drug: Maprotiline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (75 mg b.i.d.)
Study: 20669296
Drug: Melevodopa/carbidopa effervescent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melevodopa/carbidopa effervescent tablets (M/C)
Study: 20669296
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral formulation levodopa/carbidopa tablets (L/C)
Study: 16013016
Drug: Biocompatible treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biocompatible treatments (on-line hemofiltration or HD with ultra-pure dialysate and biocompatible membranes)
Study: 16013016
Drug: Biocompatible treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biocompatible treatments
Study: 9624239
Drug: low‐dose short‐term
Approvals — FDA: no, EMA: no, PMDA: no
Description: low‐dose short‐term chemotherapy (one cycle of doxorubicin, vincristin (AV) and one cycle of cyclophosphamide, methotrexate, fluorouracil (CMF))
Study: 8091320
Drug: Ventstream nebuliser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventstream nebuliser at 5.0 mg dose
Study: 27546446
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (36 IU)
Study: 22406757
Drug: 0.4 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg of alcohol
Study: 18759645
Drug: Methylphenidate transdermal
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate transdermal system (MTS) 10, 15, 20, or 30 mg/9 h
Study: 3596050
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of BCG in enteric-coated capsules
Study: 3596050
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without BCG administration
Study: 2493409
Drug: Energy‐Nitrogen Dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy‐Nitrogen Dense diet (1.5 kcal/ml; 9.4 gN/l)
Study: 2493409
Drug: Standard diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diet (1.0 kcal/ml; 6.3 gN/l)
Study: 2493409
Drug: Energy Dense
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy Dense diet (1.5 kcal/ml; 7.8 gN/l)
Study: 27995228
Drug: 15% Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% Chitosan gel
Study: 21741057
Drug: Metreleptin (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metreleptin (initial dose, 0.08 mg/[kg·d] for 3 months; altered to 0.12 mg/kg or 0.04 mg/[kg·d])
Study: 19567900
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) by a general practitioner
Study: 19567900
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Colour Your Life and TAU
Study: 9164692
Drug: linopirdine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: linopirdine (30 mg three times per day)
Study: 3299395
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg twice daily for 2 weeks
Study: 3299395
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg twice daily plus Verapamil 160 mg twice daily for 4 weeks
Study: 3299395
Drug: Verapamil 160
Normalized name: verapamil 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 160 mg twice daily for 4 weeks
Study: 28664750
Drug: Preemptive Ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preemptive Ethanol Lock Therapy (ELT)
Study: 28664750
Drug: Rescue Ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rescue Ethanol Lock Therapy (ELT)
Study: 26917477
Drug: Gestrinone 2.5
Normalized name: gestrinone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone 2.5 mg, twice a week for three months
Study: 26917477
Drug: Gestrinone double
Normalized name: gestrinone
DrugBank: Gestrinone (DB11619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone double dose first month, then twice a week for two months
Study: 26917477
Drug: Gestrinone treatment
Normalized name: gestrinone
DrugBank: Gestrinone (DB11619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone treatment
Study: 25569481
Drug: Standard-care control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-care control group (C-G)
Study: 20498392
Drug: Genetic information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic information regarding cognitive impairment risk (CI) after chemotherapy
Study: 16926710
Drug: High-dose alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose alcohol preload
Study: 8777169
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy followed by high-dose split course radiotherapy (CT + RT)
Study: 8777169
Drug: High-dose radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radiotherapy only (RT only)
Study: 1440306
Drug: Nitrendipine 20
Normalized name: nitrendipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 20 mg/day
Study: 1725550
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 120 mg/day diltiazem and 20 mg/day nitrendipine
Study: 6409196
Drug: L-Deprenil treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Deprenil treatment
Study: 22312088
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment of chronic cerebro-spinal venous insufficiency
Study: 18692615
Drug: SILCS diaphragm
Approvals — FDA: no, EMA: no, PMDA: no
Description: SILCS diaphragm with 2% nonoxynol-9 (N-9) gel
Study: 18692615
Drug: SILCS polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: SILCS polymer spring diaphragm with 2% nonoxynol-9 (N-9) gel
Study: 16062021
Drug: 0.5% 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% 20 ml bupivacaine
Study: 16062021
Drug: 0.5% 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% 20 ml bupivacaine with 1 microg/kg clonidine
Study: 12373696
Drug: 8 mL
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mL of lidocaine‐bupivacaine mixture plus 0.5 mL 0.9% NaCl (group I)
Study: 12373696
Drug: 8 mL
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mL of lidocaine‐bupivacaine mixture plus 0.5 mL (5 mg) atracurium (group II)
Study: 10544340
Drug: Tetracycline eye
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline eye ointment administered by Village Treatment Assistants (VTAs) daily for four weeks.
Study: 2093019
Drug: Omeprazole, 20
Normalized name: Omeprazole, 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 20 or 40 mg daily
Study: 2093019
Drug: Omeprazole, 20
Normalized name: Omeprazole, 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 20 mg daily (maintenance)
Study: 2093019
Drug: Omeprazole weekend
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole weekend therapy (20 mg daily on Fri, Sat, Sun)
Study: 74302
Drug: Combination schedule
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination schedule containing adriamycin
Study: 74302
Drug: Combination schedule
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination schedule without adriamycin
Study: 10629345
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or no antithrombotic therapy
Study: 1994417
Drug: Oral superparamagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral superparamagnetic contrast agent (800 mL ingested over approximately 2 hours)
Study: 30644302
Drug: arthroscopic debridement
Approvals — FDA: no, EMA: no, PMDA: no
Description: arthroscopic debridement and a subsequent intra‐articular injection of autologous micro‐fragmented adipose tissue
Study: 26691932
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied immediately after extraction
Study: 21692147
Drug: Theoretical formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theoretical formulations regarding medial temporal contributions
Study: 17599424
Drug: Comprehensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive therapy for diabetes-related dyslipidemia
Study: 2012453
Drug: Full-dosage zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-dosage zidovudine (1200 mg/d)
Study: 2012453
Drug: Reduced dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced dosage zidovudine (600 mg/d)
Study: 2012453
Drug: No dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: No dosage change
Study: 7258744
Drug: Combination drug
Normalized name: combination drugs used in erectile dysfunction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination drug product containing triprolidine and pseudoephedrine
Study: 31430763
Drug: 670 nm red
Normalized name: Red gum
DrugBank: Eucalyptus gum (DB15537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 670 nm red light treatment (15 min daily until 34 weeks corrected age, 9 J/cm2)
Study: 22316314
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D supplementation (average daily dose 10,200 IU)
Study: 22316314
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin D supplementation (average daily dose 200 IU)
Study: 22316314
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin D supplementation
Study: 15101856
Drug: Ropivacaine-HCl 5
Normalized name: Ropivacaine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine-HCl 5 mg ml(-1)
Study: 15101856
Drug: Levobupivacaine-HCl 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine-HCl 5 mg ml(-1)
Study: 15101856
Drug: Bupivacaine-HCl 5
Normalized name: Bupivacaine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine-HCl 5 mg ml(-1)
Study: 12221843
Drug: Medication plus
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication plus carbon dioxide baths
Study: 9818665
Drug: Intraarticular hyaluronic
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular hyaluronic acid (HA; Hyalgan) 20 mg each for 5 weekly injections
Study: 8131527
Drug: Terbutaline dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline dry powder inhaled via Turbuhaler (2.5 mg)
Study: 8131527
Drug: Terbutaline inhaled
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline inhaled via CFC inhaler and Nebuhaler (2.5 mg)
Study: 2401100
Drug: Naloxone, 4
Normalized name: Buprenorphine-Naloxone, 4 mg-1 mg sublingual film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone, 4 mg bolus and 6 mg/h intravenously
Study: 2401100
Drug: Saline, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline, administered intravenously
Study: 2401100
Drug: Naloxone, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone, administered intravenously
Study: 7437134
Drug: FK 33‐824
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK 33‐824 (1.25 mg, i.m.)
Study: 7437134
Drug: Morphine HCL
Normalized name: morphine HCl
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine HCL (20 mg, i.m.)
Study: 27910088
Drug: Bupivacaine (GON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (GON blockade administered four times, once per week)
Study: 27910088
Drug: Placebo (saline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline, GON blockade administered four times, once per week)
Study: 25688820
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (1 gram)
Study: 15167329
Drug: Home glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home glucose records in computer‐assisted insulin dose adjustment
Study: 15167329
Drug: Pocket‐sized insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pocket‐sized insulin dosage computers
Study: 9484382
Drug: Intramuscular ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ketorolac 60 mg
Study: 8707552
Drug: Meperidine 50
Normalized name: meperidine 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 50 mg plus promethazine 25 mg
Study: 23590647
Drug: Psychoprophylaxis childbirth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoprophylaxis childbirth preparation (coaching training)
Study: 23590647
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care antenatal preparation (no coaching training)
Study: 21406094
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol 100 mcg twice daily started at induction of anaesthesia and continued for 72 hours thereafter
Study: 21406094
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol 100 mcg twice daily
Study: 16890832
Drug: Scheduled treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled treatment interruptions
Study: 24962326
Drug: In-Prison buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-Prison buprenorphine Treatment Condition
Study: 24342495
Drug: Antithrombin at
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin at a dose of 30 IU/kg per day for three days
Study: 24342495
Drug: Antithrombin treatment
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin treatment
Study: 17394534
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and Glibenclamide
Study: 17300951
Drug: Atorvastatin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin plus aspirin combined therapy
Study: 8783345
Drug: Teicoplanin 10
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 10 mg/kg/day (Group A)
Study: 8783345
Drug: Teicoplanin 20
Normalized name: Teicoplanin 200 mg powder for solution for injection vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 20 mg/kg/day (Group B)
Study: 3006226
Drug: Intravenous Acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Acyclovir (ACV) 10 mg/kg every 8 h for 7 days
Study: 26865043
Drug: Ticagrelor 180
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg loading dose, followed by 90 mg twice daily after PCI
Study: 26865043
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg loading dose, followed by 75 mg once daily after PCI
Study: 22410586
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block with 0.5% ropivacaine 1.5 mg/kg
Study: 14713566
Drug: Biological interventions
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological interventions